<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085639</url>
  </required_header>
  <id_info>
    <org_study_id>CoV2-002</org_study_id>
    <nct_id>NCT05085639</nct_id>
  </id_info>
  <brief_title>GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)</brief_title>
  <official_title>Phase I Study of the Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study of the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against&#xD;
      SARS-CoV-2 (COVID-19)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I, randomized, placebo-controlled, dose-ranging, single-blind study will assess&#xD;
      the safety, tolerability, and immunogenicity of GLS-5310 DNA vaccine administered&#xD;
      intradermally (ID) with or without concomitant intranasal (IN) administration of GLS-5310.&#xD;
      Vaccine delivered ID will either be performed by Mantoux injection and followed by suction&#xD;
      applied to the skin surface using the Gene-Derm device or Mantous injection alone without&#xD;
      applied suction. Vaccine delivered IN will be administered using the MAD300 atomizer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
    <description>solicited/unsolicited local and systemic AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) of antigen specific antibody titers</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
    <description>Endpoint titer of binding antibody in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of positive response rate of T cell responses induced by GLS-5310</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
    <description>T-cell response of antigen-specific interferon - gamma (IFN-γ) secretion in PBMC at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of neutralizing antibody titers</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
    <description>Plaque-reduction neutralizing titer(PRNT) in serum at each timepoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine IgG antibody responses after a single dose of GLS-5310 related to treatment arm</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
    <description>Endpoint titer of binding antibody in serum at each timepoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine IgA antibody responses following vaccination of GLS-5310 related to treatment arm</measure>
    <time_frame>Through 56 weeks post vaccination</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLS-5310 1.2 mg (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5310 1.2 mg (ID + Gene-Derm) at Day 0 and Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-5310 2.4 mg (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5310 1.2 mg (ID + Gene-Derm) + 1.2 mg (IN) at Day 0 and Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-5310 1.2 mg (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5310 1.2 mg ID at Day 0 and Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group 4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (ID + Gene-Derm) at Day 0 and Week 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLS-5130</intervention_name>
    <description>GLS-5310 DNA plasmid vaccine</description>
    <arm_group_label>GLS-5310 1.2 mg (Group 1)</arm_group_label>
    <arm_group_label>GLS-5310 1.2 mg (Group 3)</arm_group_label>
    <arm_group_label>GLS-5310 2.4 mg (Group 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (Group 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age 18 to 65 years of age&#xD;
&#xD;
          2. Able to provide informed consent&#xD;
&#xD;
          3. Able and willing to comply with study procedures&#xD;
&#xD;
          4. For women of childbearing potential, able and willing to use an approved form of&#xD;
             pregnancy prevention during the study&#xD;
&#xD;
          5. Negative test result for the presence of SARS-CoV-2 IgM and IgG antibodies, which&#xD;
             indicate recent or prior infection&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Persons involved in the care of patients with COVID-19 and health care workers&#xD;
             considered, in the opinion of the investigator, to be at increased risk of infection&#xD;
             from SARS-CoV-2&#xD;
&#xD;
          2. Persons with symptoms in the past 2 weeks consistent with possible acute SARS-CoV-2&#xD;
             infection to include fever, loss of smell or taste&#xD;
&#xD;
          3. Persons diagnosis of type 2 diabetes mellitus&#xD;
&#xD;
          4. Persons with a diagnosis of chronic kidney disease&#xD;
&#xD;
          5. Persons with a diagnosis of chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          6. Persons with a diagnosis of heart conditions to include heart failure, coronary artery&#xD;
             disease, prior heart attack, cardiomyopathy&#xD;
&#xD;
          7. Obesity (BMI of 30 kg/m2 or greater)&#xD;
&#xD;
          8. Sickle cell disease&#xD;
&#xD;
          9. Current or former smoker&#xD;
&#xD;
         10. Current or planned pregnancy during the study&#xD;
&#xD;
         11. Currently breastfeeding&#xD;
&#xD;
         12. Current or past participation in a coronavirus (MERS-CoV, SARS-CoV-2) vaccine study,&#xD;
             or receipt of a SARS-CoV-2 vaccine that has been approved by the FDA, including&#xD;
             vaccines that have received Emergency Use Authorization (EUA)&#xD;
&#xD;
         13. Administration of an investigational agent within 90 days of the 1st dose&#xD;
&#xD;
         14. Administration of a vaccine within 2 weeks prior to the 1st dose&#xD;
&#xD;
         15. Administration of immune globulin within 6 months of enrollment&#xD;
&#xD;
         16. Administration of an anti-TNFα inhibitor such as infliximab, adalimumab, etanercept,&#xD;
             or anti-CD20 monoclonal antibody rituximab within 6 months from enrollment&#xD;
&#xD;
         17. Current daily treatment of systemic corticosteroids of 20 mg of prednisone or greater;&#xD;
             or the equivalent dose of other systemic corticosteroids&#xD;
&#xD;
         18. Treatment within the four weeks prior to enrollment with any drug intended for the&#xD;
             prophylaxis or treatment of COVID-19&#xD;
&#xD;
         19. Any prior treatment with an anti-SARS-CoV-2 monoclonal antibody or immune serum&#xD;
&#xD;
         20. Prior treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal&#xD;
             antibody, or anti-JAK inhibitor (see Appendix B exclusionary period for specific&#xD;
             drugs)&#xD;
&#xD;
         21. History of malignancy&#xD;
&#xD;
         22. History of transplantation (any organ or bone marrow)&#xD;
&#xD;
         23. Current or planned chemotherapy treatment for hematologic or solid tumor during study&#xD;
             period&#xD;
&#xD;
         24. History of other congenital or acquired immunodeficiency, excluding those with HIV&#xD;
             infection who are taking highly active antiretroviral therapy and who have&#xD;
             documentation of undetectable serum viral load&#xD;
&#xD;
         25. History of PCR-confirmed infection with SARS-CoV-2&#xD;
&#xD;
         26. Not willing to allow storage and future use of samples for SARS-CoV-2 related research&#xD;
             and who have a CD4 count &gt; 200 cells/µL on two measures at least 3 months apart&#xD;
&#xD;
         27. Prisoner or subjects who are compulsorily detained for treatment of a psychiatric&#xD;
             illness&#xD;
&#xD;
         28. Any illness or condition that, in the opinion of the investigator, may affect the&#xD;
             safety of the subject or the evaluation of a study endpoint&#xD;
&#xD;
             Exclusion criteria (ID + IN only):&#xD;
&#xD;
         29. History of chronic rhinosinusitis&#xD;
&#xD;
         30. History of nasal septal defect or deviated nasal septum&#xD;
&#xD;
         31. History of cleft palate&#xD;
&#xD;
         32. History of nasal polyps&#xD;
&#xD;
         33. History of other disorders that, in the opinion of the investigator, may adversely&#xD;
             affect administration of intranasal vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>610-707-5671</phone>
    <email>jmaslow@genels.us</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <phone>914-606-1199</phone>
    <email>dkane@genels.us</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <investigator>
      <last_name>Javier Morales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00963</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <contact>
      <last_name>Ileana Boneta</last_name>
      <phone>787-767-9192</phone>
    </contact>
    <investigator>
      <last_name>Jorge Santana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

